A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA nephropathy - PubMed
4 hours ago
- #adrenal insufficiency
- #IgA nephropathy
- #Nefecon
- A patient with IgAN developed cushingoid features, weight gain, hyperglycemia, and leukocytosis within 3 months of starting Nefecon.
- During dose tapering, symptomatic adrenal insufficiency occurred, confirmed by low morning cortisol and necessitating hydrocortisone replacement.
- Despite its targeted-release design for minimal systemic exposure, Nefecon caused clinically significant adverse effects and adrenal suppression.
- The case highlights the need for careful monitoring and patient education during initiation and tapering of Nefecon in IgAN management.